Urinary Incontinence Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Description
Growth Factors of urinary incontinence devices Market
The global urinary incontinence devices market is poised for steady growth in the coming decade, driven by rising awareness, technological innovations, and increasing prevalence of chronic conditions. According to Fortune Business Insights, the market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.7 billion in 2026, eventually reaching USD 7.48 billion by 2034, representing a CAGR of 6.0% during the forecast period. In 2025, North America dominated the market with a 42.5% share, reflecting the region’s advanced healthcare infrastructure, favorable reimbursement policies, and strong technological adoption.
Urinary incontinence devices help prevent urine leakage, improve comfort, and enhance mobility and independence, particularly among the aging population. The rising prevalence of conditions such as diabetes, obesity, urinary tract infections, and neurological disorders is increasing the demand for these devices globally. For example, as per 2025 data published by ScienceDirect, approximately 40% of the population in Europe suffers from urinary incontinence. Key players including Coloplast A/S, Convatec Inc., and Essity Aktiebolag are actively focusing on R&D initiatives to develop innovative and technologically advanced products to enhance patient care.
Market Dynamics
Drivers
The growing incidence of acute and chronic diseases, coupled with an aging population, is a major driver of market growth. According to the NCBI (2025), the global prevalence of urinary incontinence was around 32.4%, highlighting the widespread need for effective solutions. Rising awareness, reduced stigma, and better reimbursement policies further encourage adoption. By 2030, one in six people globally is expected to be aged 60 or above, supporting the long-term demand for these devices.
Restraints
Market growth is constrained by limited diagnosis and reimbursement policies in developing nations, particularly in Brazil, China, and India. Delayed referrals and a lack of clinical expertise in chronic conditions result in postponed diagnosis and treatment. For instance, the Brazilian Public Health System does not cover pharmacotherapy for urge urinary incontinence, limiting access to advanced devices in the region.
Opportunities
Technological innovations in absorbent and non-absorbent products, including smart sensors, mobile apps, and non-invasive neuromodulation devices, are reshaping the market. For example, in February 2025, UroMems announced that female patients treated with UroActive Smart Implants successfully reached six-month primary endpoints, demonstrating clinical effectiveness. These advancements provide opportunities for key players to expand their portfolios and address unmet patient needs.
Challenges
High device costs hinder adoption, especially in emerging economies. Urinary incontinence slings range from USD 10 to over USD 10,000, limiting patient access. Additional challenges include surgical risks, device failures, regulatory hurdles, and competition from alternative treatments like behavioral therapy or pharmacological options.
Market Trends
A notable trend is the shift toward minimally invasive surgeries, driven by faster recovery, reduced pain, and shorter hospital stays. Technologies such as mid-urethral slings and robotic-assisted platforms are gaining traction. According to a 2024 study by the International Continence Society, mid-urethral sling insertions showed reoperation rates of only 0.8% at one year and 2.7% at five years, highlighting improved outcomes and patient satisfaction.
Segmentation Analysis
By Product Type
The market is segmented into absorbents and non-absorbents, with absorbents—including underwear, briefs, pads, and bed protectors—dominating 67.02% of the market in 2026. Non-absorbent products include slings, catheters, urethral inserts, stimulation devices, and drainage bags.
By Gender
The female segment dominated in 2026 with a 64.89% share, due to higher prevalence rates among women. According to 2025 Phoenix Physical Therapy data, one in four women over 18 in the U.S. experiences some form of urinary incontinence. The male segment is projected to grow at a CAGR of 4.9% during the forecast period.
By Usage
The disposable segment led in 2026 with 58.3% share, driven by convenience and hygiene benefits. Reusable products are expected to grow at a CAGR of 5.4%.
By End User
Homecare settings dominated in 2025, with an anticipated 44.47% market share in 2026, due to patient preference for at-home treatment and adequate reimbursement policies. Hospitals and ASCs are projected to grow at a CAGR of 5.7%.
Regional Outlook
North America: USD 1.93 billion in 2025, USD 2.0 billion in 2026; U.S. market at USD 1.84 billion in 2026.
Europe: USD 1.31 billion in 2025; U.K. USD 0.26 billion, Germany USD 0.32 billion, France USD 0.22 billion in 2025–2026.
Asia Pacific: USD 0.97 billion in 2026; India USD 0.15 billion, China USD 0.33 billion, Japan USD 0.26 billion.
Latin America: USD 0.23 billion in 2025.
Middle East & Africa (GCC): USD 0.05 billion in 2025.
Competitive Landscape
The market is highly competitive, led by Essity Aktiebolag, Medtronic, Coloplast A/S, BD, Teleflex, and Johnson & Johnson, who focus on product innovation, regulatory approvals, and geographic expansion. Notable developments include:
June 2025 – Neuspera Medical received FDA approval for its iSNM system for urge urinary incontinence.
March 2025 – Caldera Medical acquired Ethicon’s GYNECARE TVT products for stress urinary incontinence.
September 2024 – Medline Industries launched wetness-sensing briefs with real-time alerts.
Conclusion
The global urinary incontinence devices market is projected to grow from USD 4.53 billion in 2025 to USD 7.48 billion by 2034, driven by rising prevalence of chronic conditions, technological advancements, and homecare adoption. While challenges such as high device costs and limited reimbursement in emerging markets persist, innovations in minimally invasive devices, smart sensors, and patient-centric solutions are expected to significantly expand market penetration and improve patient outcomes worldwide.
ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 6.0% from 2026-2034
Unit Value (USD Billion)
Segmentation By Product Type, Gender, Usage, End User, and Region
By Product TypeAbsorbents Underwear & Briefs Pads & Guards Drip Collectors & Bed Protectors Non-Absorbents Urethral Inserts Slings Catheters Stimulation Devices Drainage Bags Others By Gender Male Female By Usage Reusable Disposable By End User Hospitals & ASCs Clinics Homecare Settings Others By Region North America (By Product Type, Gender, Usage, End User, and Country) U.S. (By Usage) Canada (By Usage) Europe (By Product Type, Gender, Usage, End User, and Country/Sub-region) U.K. (By Usage) Germany (By Usage) France (By Usage) Italy (By Usage) Spain (By Usage) Scandinavia (By Usage) Rest of Europe (By Usage) Asia Pacific (By Product Type, Gender, Usage, End User, and Country/Sub-region) China (By Usage) Japan (By Usage) India (By Usage) Australia (By Usage) Southeast Asia (By Usage) Rest of Asia Pacific (By Usage) Latin America (By Product Type, Gender, Usage, End User, and Country/Sub-region) Brazil (By Usage) Mexico (By Usage) Rest of Latin America (By Usage) Middle East & Africa (By Product Type, Gender, Usage, End User, and Country/Sub-region) GCC (By Usage) South Africa (By Usage) Rest of the Middle East & Africa (By Usage)
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
The global urinary incontinence devices market is poised for steady growth in the coming decade, driven by rising awareness, technological innovations, and increasing prevalence of chronic conditions. According to Fortune Business Insights, the market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.7 billion in 2026, eventually reaching USD 7.48 billion by 2034, representing a CAGR of 6.0% during the forecast period. In 2025, North America dominated the market with a 42.5% share, reflecting the region’s advanced healthcare infrastructure, favorable reimbursement policies, and strong technological adoption.
Urinary incontinence devices help prevent urine leakage, improve comfort, and enhance mobility and independence, particularly among the aging population. The rising prevalence of conditions such as diabetes, obesity, urinary tract infections, and neurological disorders is increasing the demand for these devices globally. For example, as per 2025 data published by ScienceDirect, approximately 40% of the population in Europe suffers from urinary incontinence. Key players including Coloplast A/S, Convatec Inc., and Essity Aktiebolag are actively focusing on R&D initiatives to develop innovative and technologically advanced products to enhance patient care.
Market Dynamics
Drivers
The growing incidence of acute and chronic diseases, coupled with an aging population, is a major driver of market growth. According to the NCBI (2025), the global prevalence of urinary incontinence was around 32.4%, highlighting the widespread need for effective solutions. Rising awareness, reduced stigma, and better reimbursement policies further encourage adoption. By 2030, one in six people globally is expected to be aged 60 or above, supporting the long-term demand for these devices.
Restraints
Market growth is constrained by limited diagnosis and reimbursement policies in developing nations, particularly in Brazil, China, and India. Delayed referrals and a lack of clinical expertise in chronic conditions result in postponed diagnosis and treatment. For instance, the Brazilian Public Health System does not cover pharmacotherapy for urge urinary incontinence, limiting access to advanced devices in the region.
Opportunities
Technological innovations in absorbent and non-absorbent products, including smart sensors, mobile apps, and non-invasive neuromodulation devices, are reshaping the market. For example, in February 2025, UroMems announced that female patients treated with UroActive Smart Implants successfully reached six-month primary endpoints, demonstrating clinical effectiveness. These advancements provide opportunities for key players to expand their portfolios and address unmet patient needs.
Challenges
High device costs hinder adoption, especially in emerging economies. Urinary incontinence slings range from USD 10 to over USD 10,000, limiting patient access. Additional challenges include surgical risks, device failures, regulatory hurdles, and competition from alternative treatments like behavioral therapy or pharmacological options.
Market Trends
A notable trend is the shift toward minimally invasive surgeries, driven by faster recovery, reduced pain, and shorter hospital stays. Technologies such as mid-urethral slings and robotic-assisted platforms are gaining traction. According to a 2024 study by the International Continence Society, mid-urethral sling insertions showed reoperation rates of only 0.8% at one year and 2.7% at five years, highlighting improved outcomes and patient satisfaction.
Segmentation Analysis
By Product Type
The market is segmented into absorbents and non-absorbents, with absorbents—including underwear, briefs, pads, and bed protectors—dominating 67.02% of the market in 2026. Non-absorbent products include slings, catheters, urethral inserts, stimulation devices, and drainage bags.
By Gender
The female segment dominated in 2026 with a 64.89% share, due to higher prevalence rates among women. According to 2025 Phoenix Physical Therapy data, one in four women over 18 in the U.S. experiences some form of urinary incontinence. The male segment is projected to grow at a CAGR of 4.9% during the forecast period.
By Usage
The disposable segment led in 2026 with 58.3% share, driven by convenience and hygiene benefits. Reusable products are expected to grow at a CAGR of 5.4%.
By End User
Homecare settings dominated in 2025, with an anticipated 44.47% market share in 2026, due to patient preference for at-home treatment and adequate reimbursement policies. Hospitals and ASCs are projected to grow at a CAGR of 5.7%.
Regional Outlook
North America: USD 1.93 billion in 2025, USD 2.0 billion in 2026; U.S. market at USD 1.84 billion in 2026.
Europe: USD 1.31 billion in 2025; U.K. USD 0.26 billion, Germany USD 0.32 billion, France USD 0.22 billion in 2025–2026.
Asia Pacific: USD 0.97 billion in 2026; India USD 0.15 billion, China USD 0.33 billion, Japan USD 0.26 billion.
Latin America: USD 0.23 billion in 2025.
Middle East & Africa (GCC): USD 0.05 billion in 2025.
Competitive Landscape
The market is highly competitive, led by Essity Aktiebolag, Medtronic, Coloplast A/S, BD, Teleflex, and Johnson & Johnson, who focus on product innovation, regulatory approvals, and geographic expansion. Notable developments include:
June 2025 – Neuspera Medical received FDA approval for its iSNM system for urge urinary incontinence.
March 2025 – Caldera Medical acquired Ethicon’s GYNECARE TVT products for stress urinary incontinence.
September 2024 – Medline Industries launched wetness-sensing briefs with real-time alerts.
Conclusion
The global urinary incontinence devices market is projected to grow from USD 4.53 billion in 2025 to USD 7.48 billion by 2034, driven by rising prevalence of chronic conditions, technological advancements, and homecare adoption. While challenges such as high device costs and limited reimbursement in emerging markets persist, innovations in minimally invasive devices, smart sensors, and patient-centric solutions are expected to significantly expand market penetration and improve patient outcomes worldwide.
ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 6.0% from 2026-2034
Unit Value (USD Billion)
Segmentation By Product Type, Gender, Usage, End User, and Region
By Product Type
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
Table of Contents
261 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Development of Cell and Gene Therapy for New Disease Indications
- 4.2. Regulatory Scenarios, By Key Countries/Regions
- 4.3. Technological Advancements in the Market
- 4.4. New Product Launches, By Key Players
- 4.5. Pipeline Analysis, By Key Companies
- 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
- 4.7. Pricing & Reimbursement Landscape in the Market
- 4.8. Manufacturing & Supply Chain Insights
- 4.9. Investment & Funding Trends in the Market
- 4.10. Overview: Patient Access to the Therapy & Ethical Considerations
- 5. Global Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast – By Type
- 5.1.1. Cell Therapy
- 5.1.1.1. Therapy Type
- 5.1.1.1.1. CAR-T Cell Therapy
- 5.1.1.1.2. TCR-T Cell Therapy
- 5.1.1.1.3. Natural Killer (NK) Cells
- 5.1.1.1.4. Others
- 5.1.1.2. Product Type
- 5.1.1.2.1. Kymriah
- 5.1.1.2.2. Yescarta
- 5.1.1.2.3. Tecartus
- 5.1.1.2.4. Breyanzi
- 5.1.1.2.5. Abecma
- 5.1.1.2.6. Carvykti
- 5.1.1.2.7. Others
- 5.1.1.3. Indication
- 5.1.1.3.1. Oncology
- 5.1.1.3.2. Others
- 5.1.2. Gene Therapy
- 5.1.2.1. Product Type
- 5.1.2.1.1. Zolgensma
- 5.1.2.1.2. Luxturna
- 5.1.2.1.3. Roctavian
- 5.1.2.1.4. Others
- 5.1.2.2. Vector Type
- 5.1.2.2.1. Viral Vectors
- 5.1.2.2.2. Non-Viral Vectors
- 5.1.2.3. Indication
- 5.1.2.3.1. Genetic Disorders
- 5.1.2.3.2. Ophthalmology
- 5.1.2.3.3. Hematology
- 5.1.2.3.4. Others
- 5.2. Market Analysis, Insights and Forecast – By End User
- 5.2.1. Hospitals & Clinics
- 5.2.2. Specialty Clinics
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Latin America
- 5.3.5. Middle East & Africa
- 6. North America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast – By Type
- 6.1.1. Cell Therapy
- 6.1.1.1. Therapy Type
- 6.1.1.1.1. CAR-T Cell Therapy
- 6.1.1.1.2. TCR-T Cell Therapy
- 6.1.1.1.3. Natural Killer (NK) Cells
- 6.1.1.1.4. Others
- 6.1.1.2. Product Type
- 6.1.1.2.1. Kymriah
- 6.1.1.2.2. Yescarta
- 6.1.1.2.3. Tecartus
- 6.1.1.2.4. Breyanzi
- 6.1.1.2.5. Abecma
- 6.1.1.2.6. Carvykti
- 6.1.1.2.7. Others
- 6.1.1.3. Indication
- 6.1.1.3.1. Oncology
- 6.1.1.3.2. Others
- 6.1.2. Gene Therapy
- 6.1.2.1. Product Type
- 6.1.2.1.1. Zolgensma
- 6.1.2.1.2. Luxturna
- 6.1.2.1.3. Roctavian
- 6.1.2.1.4. Others
- 6.1.2.2. Vector Type
- 6.1.2.2.1. Viral Vectors
- 6.1.2.2.2. Non-Viral Vectors
- 6.1.2.3. Indication
- 6.1.2.3.1. Genetic Disorders
- 6.1.2.3.2. Ophthalmology
- 6.1.2.3.3. Hematology
- 6.1.2.3.4. Others
- 6.2. Market Analysis, Insights and Forecast – By End User
- 6.2.1. Hospitals & Clinics
- 6.2.2. Specialty Clinics
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast – By Country
- 6.3.1. U.S.
- 6.3.2. Canada
- 7. Europe Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast – By Type
- 7.1.1. Cell Therapy
- 7.1.1.1. Therapy Type
- 7.1.1.1.1. CAR-T Cell Therapy
- 7.1.1.1.2. TCR-T Cell Therapy
- 7.1.1.1.3. Natural Killer (NK) Cells
- 7.1.1.1.4. Others
- 7.1.1.2. Product Type
- 7.1.1.2.1. Kymriah
- 7.1.1.2.2. Yescarta
- 7.1.1.2.3. Tecartus
- 7.1.1.2.4. Breyanzi
- 7.1.1.2.5. Abecma
- 7.1.1.2.6. Carvykti
- 7.1.1.2.7. Others
- 7.1.1.3. Indication
- 7.1.1.3.1. Oncology
- 7.1.1.3.2. Others
- 7.1.2. Gene Therapy
- 7.1.2.1. Product Type
- 7.1.2.1.1. Zolgensma
- 7.1.2.1.2. Luxturna
- 7.1.2.1.3. Roctavian
- 7.1.2.1.4. Others
- 7.1.2.2. Vector Type
- 7.1.2.2.1. Viral Vectors
- 7.1.2.2.2. Non-Viral Vectors
- 7.1.2.3. Indication
- 7.1.2.3.1. Genetic Disorders
- 7.1.2.3.2. Ophthalmology
- 7.1.2.3.3. Hematology
- 7.1.2.3.4. Others
- 7.2. Market Analysis, Insights and Forecast – By End User
- 7.2.1. Hospitals & Clinics
- 7.2.2. Specialty Clinics
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.3.1. Germany
- 7.3.2. U.K.
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Scandinavia
- 7.3.7. Rest of Europe
- 8. Asia Pacific Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast – By Type
- 8.1.1. Cell Therapy
- 8.1.1.1. Therapy Type
- 8.1.1.1.1. CAR-T Cell Therapy
- 8.1.1.1.2. TCR-T Cell Therapy
- 8.1.1.1.3. Natural Killer (NK) Cells
- 8.1.1.1.4. Others
- 8.1.1.2. Product Type
- 8.1.1.2.1. Kymriah
- 8.1.1.2.2. Yescarta
- 8.1.1.2.3. Tecartus
- 8.1.1.2.4. Breyanzi
- 8.1.1.2.5. Abecma
- 8.1.1.2.6. Carvykti
- 8.1.1.2.7. Others
- 8.1.1.3. Indication
- 8.1.1.3.1. Oncology
- 8.1.1.3.2. Others
- 8.1.2. Gene Therapy
- 8.1.2.1. Product Type
- 8.1.2.1.1. Zolgensma
- 8.1.2.1.2. Luxturna
- 8.1.2.1.3. Roctavian
- 8.1.2.1.4. Others
- 8.1.2.2. Vector Type
- 8.1.2.2.1. Viral Vectors
- 8.1.2.2.2. Non-Viral Vectors
- 8.1.2.3. Indication
- 8.1.2.3.1. Genetic Disorders
- 8.1.2.3.2. Ophthalmology
- 8.1.2.3.3. Hematology
- 8.1.2.3.4. Others
- 8.2. Market Analysis, Insights and Forecast – By End User
- 8.2.1. Hospitals & Clinics
- 8.2.2. Specialty Clinics
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Southeast Asia
- 8.3.6. Rest of Asia Pacific
- 9. Latin America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast – By Type
- 9.1.1. Cell Therapy
- 9.1.1.1. Therapy Type
- 9.1.1.1.1. CAR-T Cell Therapy
- 9.1.1.1.2. TCR-T Cell Therapy
- 9.1.1.1.3. Natural Killer (NK) Cells
- 9.1.1.1.4. Others
- 9.1.1.2. Product Type
- 9.1.1.2.1. Kymriah
- 9.1.1.2.2. Yescarta
- 9.1.1.2.3. Tecartus
- 9.1.1.2.4. Breyanzi
- 9.1.1.2.5. Abecma
- 9.1.1.2.6. Carvykti
- 9.1.1.2.7. Others
- 9.1.1.3. Indication
- 9.1.1.3.1. Oncology
- 9.1.1.3.2. Others
- 9.1.2. Gene Therapy
- 9.1.2.1. Product Type
- 9.1.2.1.1. Zolgensma
- 9.1.2.1.2. Luxturna
- 9.1.2.1.3. Roctavian
- 9.1.2.1.4. Others
- 9.1.2.2. Vector Type
- 9.1.2.2.1. Viral Vectors
- 9.1.2.2.2. Non-Viral Vectors
- 9.1.2.3. Indication
- 9.1.2.3.1. Genetic Disorders
- 9.1.2.3.2. Ophthalmology
- 9.1.2.3.3. Hematology
- 9.1.2.3.4. Others
- 9.2. Market Analysis, Insights and Forecast – By End User
- 9.2.1. Hospitals & Clinics
- 9.2.2. Specialty Clinics
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 9.3.1. Brazil
- 9.3.2. Mexico
- 9.3.3. Rest of Latin America
- 10. Middle East & Africa Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast – By Type
- 10.1.1. Cell Therapy
- 10.1.1.1. Therapy Type
- 10.1.1.1.1. CAR-T Cell Therapy
- 10.1.1.1.2. TCR-T Cell Therapy
- 10.1.1.1.3. Natural Killer (NK) Cells
- 10.1.1.1.4. Others
- 10.1.1.2. Product Type
- 10.1.1.2.1. Kymriah
- 10.1.1.2.2. Yescarta
- 10.1.1.2.3. Tecartus
- 10.1.1.2.4. Breyanzi
- 10.1.1.2.5. Abecma
- 10.1.1.2.6. Carvykti
- 10.1.1.2.7. Others
- 10.1.1.3. Indication
- 10.1.1.3.1. Oncology
- 10.1.1.3.2. Others
- 10.1.2. Gene Therapy
- 10.1.2.1. Product Type
- 10.1.2.1.1. Zolgensma
- 10.1.2.1.2. Luxturna
- 10.1.2.1.3. Roctavian
- 10.1.2.1.4. Others
- 10.1.2.2. Vector Type
- 10.1.2.2.1. Viral Vectors
- 10.1.2.2.2. Non-Viral Vectors
- 10.1.2.3. Indication
- 10.1.2.3.1. Genetic Disorders
- 10.1.2.3.2. Ophthalmology
- 10.1.2.3.3. Hematology
- 10.1.2.3.4. Others
- 10.2. Market Analysis, Insights and Forecast – By End User
- 10.2.1. Hospitals & Clinics
- 10.2.2. Specialty Clinics
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 10.3.1. GCC
- 10.3.2. South Africa
- 10.3.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
- 11.2.1. Vertex Pharmaceuticals Incorporated
- 11.2.2. Krystal Biotech, Inc.
- 11.2.3. Rocket Pharmaceuticals
- 11.2.4. CRISPR Therapeutics
- 11.2.5. Bayer AG
- 11.2.6. Novartis AG
- 11.2.7. Gilead Sciences, Inc.
- 11.2.8. F. Hoffmann-La Roche Ltd (Spark Therapeutics)
- 11.2.9. Bristol-Myers Squibb Company
- 11.2.10. Adaptimmune
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
